Copyright
©The Author(s) 2024.
World J Virol. Mar 25, 2024; 13(1): 89104
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.89104
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.89104
Table 1 Patient demographics of the chronic hepatitis group
| Patient demographics | Number of patients | Percentage | |
| Sex | Female | 1 | 11.1 |
| Male | 8 | 88.9 | |
| Malignancy | ALL | 1 | 11.1 |
| Colon | 2 | 22.2 | |
| HCC | 5 | 55.6 | |
| Pancreas | 1 | 11.1 | |
| USG | Coarse liver | 5 | 55.6 |
| Normal | 4 | 44.4 | |
| Past history of jaundice | No | 4 | 44.4 |
| Yes | 5 | 55.6 | |
| Positive family history | No | 8 | 88.9 |
| Yes | 1 | 11.1 | |
| Past history of surgeries | No | 8 | 88.9 |
| Yes | 1 | 11.1 | |
| History of transfusion in the past | No | 8 | 88.9 |
| Yes | 1 | 11.1 | |
| History of acute hepatitis B in the past | No | 6 | 66.6 |
| Yes | 3 | 33.3 | |
Table 2 Baseline hepatitis B virus DNA levels of the chronic hepatitis with follow-up at 6 and 12 months after the introduction of prophylaxis (tenofovir or entecavir)
| Patient | 0 months | 6th months | 12th months | |||
| HBV DNA | Liver enzymes | HBV DNA | Liver enzymes | HBV DNA | Liver enzymes | |
| 1 | TND | Normal | TND | Normal | TND | Normal |
| 2 | TND | Normal | TND | Normal | TND | Normal |
| 3 | TND | Normal | TND | Normal | TND | Normal |
| 4 | TND | Normal | TND | Normal | TND | Normal |
| 5 | TND | Normal | TND | Normal | TND | Normal |
| 6 | TND | Normal | TND | Normal | TND | Normal |
| 7 | TND | Normal | TND | Normal | TND | Normal |
| 8 | HIGH | Elevated > 2X UNL | TND | Normal | TND | Normal |
| 9 | HIGH | Elevated > 2X UNL | TND | Normal | TND | Normal |
Table 3 Patient demographics of the occult hepatitis B infection group
| Patient demographics | No. of patients | Percentage | |
| Age | 52 yr | 1 | 33.3 |
| 75 yr | 1 | 33.3 | |
| 78 yr | 1 | 33.3 | |
| Sex | Female | 1 | 33.3 |
| Male | 2 | 66.7 | |
| Malignancy | AML | 1 | 33.3 |
| Colon | 1 | 33.3 | |
| NSGCT | 1 | 33.3 | |
| USG | Normal | 1 | 33.3 |
| Coarse liver | 2 | 66.7 | |
| History of Jaundice | Yes | 2 | 66.7 |
| No | 1 | 33.3 | |
| History of blood transfusion in the past | Yes | 1 | 33.3 |
| No | 2 | 66.7 | |
| History of surgery in the past | Yes | 1 | 33.3 |
| No | 2 | 66.7 | |
| Family history | Yes | 0 | 0.0 |
| No | 3 | 100.0 | |
Table 4 Baseline hepatitis B virus DNA levels of occult hepatitis B infection group and follow-up at 6 and 12 months after the introduction of prophylaxis (tenofovir or entecavir)
| Patient | 0 months | 6th months | 12th months | |||
| HBV DNA | Liver enzymes | HBV DNA | Liver enzymes | HBV DNA | Liver enzymes | |
| 1 | TND | Normal | TND | Normal | TND | Normal |
| 2 | TND | Normal | TND | Normal | TND | Normal |
| 3 | TND | Normal | TND | Normal | TND | Normal |
- Citation: Sudevan N, Manrai M, Tilak TVSVGK, Khurana H, Premdeep H. Chronic hepatitis B and occult infection in chemotherapy patients - evaluation in oncology and hemato-oncology settings: The CHOICE study. World J Virol 2024; 13(1): 89104
- URL: https://www.wjgnet.com/2220-3249/full/v13/i1/89104.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i1.89104
